A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Summary

The main purpose of this study is to assess efficacy and safety of orforglipron compared with oral semaglutide in participants with Type 2 diabetes and inadequate glycemic control with metformin.The study will last around 61 weeks.

Timeline

Start

2023-09-22

Primary completion

2025-08-22

Completion

2025-08-22

Outcome

Met primary endpoint

paper The primary objective of non-inferiority was met and both orforglipron doses showed superiority to both semaglutide doses, including orforglipron 12 mg versus semaglutide 14 mg. PMID 41765029 ↗

release “At 52 weeks, orforglipron met the primary and all key secondary endpoints across each dose comparison vs. oral semaglutide” lilly.com ↗

release “In ACHIEVE-3, orforglipron outperformed oral semaglutide across the primary and all key secondary endpoints, delivering significantly greater improvements in A1C and weight.” lilly.com ↗

Publications

• Rosenstock J, Yabe D, Cox D, Li J, Denning M, Wu WS, Liu R, Zhao Y; ACHIEVE-3 Investigators. Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. Lancet. 2026 Mar 21;407(10534):1147-1160. doi: 10.1016/S0140-6736(26)00202-3. Epub 2026 Feb 26.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Orforglipron	Small molecule	12 mg	Oral
Subject	Orforglipron	Small molecule	36 mg	Oral
Comparator	Semaglutide	Peptide	7 mg	Oral
Comparator	Semaglutide	Peptide	14 mg	Oral

Indications